Company / R&D Expense
Arcadia Biosciences, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$53.0K
FY2025
5-year range
$53.0K / $8.0M
FY2021-FY2025
Trend
-17.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $8M in FY2021 to $53,000 in FY2025.
Based on SEC 10-K filings.
$53,000 in FY2025 with a 5-year CAGR of -62.4%.
Declined from $2M to $53,000 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -76.1%
- 5-Year CAGR
- -62.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -62.4%, indicating a declining trend.
- In FY2025, r&d expense decreased 17.2% year-over-year.
- Peak r&d expense was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.0K | -17.2% |
| FY2024 | $64.0K | -95.8% |
| FY2023 | $1.5M | -61.2% |
| FY2022 | $3.9M | -51.1% |
| FY2021 | $8.0M | +12.1% |
| FY2020 | $7.1M | +17.0% |
| FY2019 | $6.1M | -18.1% |
| FY2018 | $7.4M | -14.5% |
| FY2017 | $8.7M | -3.4% |
| FY2016 | $9.0M | -10.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026